Imunon, Inc. (LON: 0HUZ)
London
· Delayed Price · Currency is GBP · Price in USD 0.957
+0.082 (9.32%)
Jan 23, 2025, 4:11 PM BST
Imunon Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
33
Market Cap
10.48M GBP
Revenue Chart
* This company reports financials in USD.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 38.20B |
| GSK plc | 31.31B |
| Haleon | 11.24B |
| Smith & Nephew | 4.46B |
| ConvaTec Group | 1.74B |
| Hikma Pharmaceuticals | 2.39B |
| HUTCHMED (China) | 483.31M |
| Oxford Nanopore Technologies | 167.75M |
Imunon News
- 5 weeks ago - IMUNON Announces Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian Cancer - GlobeNewsWire
- 6 weeks ago - IMUNON Announces Continued Strong Improvement in Overall Survival Data from Randomized Phase 2 OVATION 2 Study of IMNN-001 - GlobeNewsWire
- 2 months ago - IMUNON Announces Results from its End-of-Phase 2 Meeting with the FDA for its Lead IMNN-001 Clinical Program in Advanced Ovarian Cancer - GlobeNewsWire
- 2 months ago - Imunon, Inc. (IMNN) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - IMUNON Presents Positive Data from Phase 2 OVATION 2 Clinical Trial of IMNN-001 in Advanced Ovarian Cancer at SITC 39th Annual Meeting - GlobeNewsWire
- 2 months ago - IMUNON Reports Third Quarter 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 3 months ago - IMUNON to Hold Third Quarter 2024 Financial Results and Business Update Conference Call on Thursday, November 7, 2024 - GlobeNewsWire
- 3 months ago - IMUNON to Present Phase 2 Data of IMNN-001 in Treatment of Newly Diagnosed Ovarian Cancer at SITC 39th Annual Meeting - GlobeNewsWire